Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene Mutations

Explore clinical trials studying Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene Mutations. Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies

Refine in advanced search Browse all conditions

Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene Mutations trial results

Completed

Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers

NCT02849977

Conditions: Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene Mutations
Locations: Synexus Clinical Research US, Inc. - Simon Williamson Clinic, PC Birmingham, Alabama, United States

Synexus Clinical Research US, Inc. - Phoenix Southeast Chandler, Arizona, United States

Clinical Research Advantage Inc. Mesa, Arizona, United States

Tucson Neuroscience Research - M3 Wake Research Tucson, Arizona, United States

View all 58 locations

View Trial Details